Bristol-Myers to introduce 8 drugs in 18 months

Bristol-Myers Squibb plans to launch eight drugs in the next 12 to 18 months, the drugmaker's COO told Business Insider

Chris Boerner, COO of Bristol-Myers, said the launches will expand the uses of some of its already approved drugs and include some new cell therapy treatments for cancer and a treatment for relapsing multiple sclerosis. 

Fedratinib, a treatment for a rare bone marrow cancer, is one of the drugs the company plans to launch in the next year. It was approved by the FDA in August. 

Bristol-Myers expects Ozanimod, a treatment for relapsing multiple sclerosis, to be approved by March, Business Insider reported. 

It also expects the FDA to make a decision by April on luspatercept, a drug that treats anemia in people with blood disorders. 

Bristol-Myers is looking to expand the use of its best-selling cancer immunotherapy drugs, Opdivo and Yervoy, to treat non-small cell lung cancer and expects the FDA to make a decision by May 15, according to Business Insider.  

The drugmaker also plans to launch liso-cell, a cell therapy designed to treat large B-cell lymphoma that it gained when it acquired Celgene.

It plans to launch TYK2, a treatment for psoriasis, after getting data from its late-stage trial in the first half of 2020. 

Ide-cel, a cell therapy to treat multiple myeloma, should be submitted to the FDA in the first half of 2020, according to Business Insider

And Bristol-Myers plans to launch CC-486, a treatment for myeloid leukemia. 

Read the full article here.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars